226916-23-0

Upstream product

• 81036-84-2 3-bromocyclohex-2-en-1-one ethylene ketal 
• 226916-17-2 3-(1,4-dioxaspiro[4.5]dec-7-en-7-yl)acrylic acid methyl ester 
• 226915-53-3 (2R)-4-hydroxypentyl-2-ynoic acid benzyl ester 
• 226916-21-8 (2R)-4-hydroxypent-(Z)-2-enoic acid benzyl ester 
• 226916-19-4 3-(1,4-dioxaspiro[4.5]dec-7-en-7-yl)acrylic acid 
• 1017854-37-3 C₂₃H₂₄O₆ 

Downstream Products

• 1017854-41-9 C₂₃H₂₆O₆ 

Relevant academic research and scientific papers

Thrombin Receptor Antagonists Based On The Modified Tricyclic Unit Of Himbacine

Multiple stereoisomers of the heterocyclic-substituted tricyclics of the formula: or a pharmaceutically acceptable salt, solvate, or ester of said compound wherein R and the stereochemistry are illustrated in the structural formulas herein are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.

Metabolism-based identification of a potent thrombin receptor antagonist

The metabolism of our prototypical thrombin receptor antagonist 1, K i = 2.7 nM, was studied and three major metabolites (2, 4, and 5) were found. The structures of the metabolites were verified independently by synthesis. Compound 4 was shown